Malignancies and cyclophosphamide exposure in Wegener's granulomatosis.

[1]  M. Urowitz,et al.  The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case–cohort study , 2007, Annals of the rheumatic diseases.

[2]  A. Loft,et al.  Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. , 2008, The Journal of rheumatology.

[3]  A. Ekbom,et al.  A closer look at non-Hodgkin’s lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study , 2007, Annals of the rheumatic diseases.

[4]  A. Iliadou,et al.  Characteristics of diffuse large B cell lymphomas in rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[5]  D. Schroeder,et al.  Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. , 2006, American journal of respiratory and critical care medicine.

[6]  P. Lamprecht,et al.  Advances in the therapy of Wegener's granulomatosis , 2006, Current opinion in rheumatology.

[7]  J. Stone.  Etanercept plus Standard Therapy for Wegener's Granulomatosis , 2005 .

[8]  W. Mccune,et al.  Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide. , 2004, The Journal of rheumatology.

[9]  C. Langford,et al.  Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. , 2004, Arthritis and rheumatism.

[10]  V. Tesar,et al.  A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. , 2003, The New England journal of medicine.

[11]  ACOG Practice Bulletin: clinical management guidelines for obstetrician-gynecologists. Number 45, August 2003. Cervical cytology screening (replaces committee opinion 152, March 1995). , 2003, Obstetrics and gynecology.

[12]  J. Askling,et al.  Cancer incidence in a population‐based cohort of patients with Wegener's granulomatosis , 2002, International journal of cancer.

[13]  M. Helfand,et al.  Screening for skin cancer. , 2001, American journal of preventive medicine.

[14]  D. Symmons,et al.  Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. , 1999, The Journal of rheumatology.

[15]  M. Haubitz,et al.  Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. , 1998, Arthritis and rheumatism.

[16]  B. Hoen,et al.  A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. , 1997, Arthritis and rheumatism.

[17]  D. Symmons,et al.  Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. , 1996, British journal of rheumatology.

[18]  Guy Hoffman,et al.  Cyclophosphamide-Induced Cystitis and Bladder Cancer in Patients with Wegener Granulomatosis , 1996, Annals of Internal Medicine.

[19]  O. Lortholary,et al.  Treatment of systemic vasculitis with cyclophosphamide and steroids: daily oral low-dose cyclophosphamide administration after failure of a pulse intravenous high-dose regimen in four patients. , 1994, British journal of rheumatology.

[20]  Guy Hoffman,et al.  Wegener Granulomatosis: An Analysis of 158 Patients , 1992, Annals of Internal Medicine.

[21]  T. Medsger,et al.  Malignancy following treatment of rheumatoid arthritis with cyclophosphamide. Long-term case-control follow-up study. , 1987, The American journal of medicine.